

ABSTRACT

J Neurooncol. 2022 Mar 4. doi: 10.1007/s11060-021-03881-w. Online ahead of print.

Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults.

Patrick HH(1), Sherman JH(2), Elder JB(3), Olson JJ(4).

Author information:

(1)Department of Neurological Surgery, George Washington University, 900 23rd St NW, Washington, DC, 20037, USA. hpatrick@gwu.edu.

(2)Department of Neurosurgery, West Virginia University Rockefeller Neuroscience Institute, Martinsburg, WV, USA.

(3)Department of Neurosurgical Oncology, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

(4)Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.

QUESTION: In patients with previously diagnosed glioblastoma who are suspected of experiencing progression, does repeat cytoreductive surgery improve progression free survival or overall survival compared to alternative interventions?

TARGET POPULATION: These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process and are amenable to surgical resection.

RECOMMENDATION: Level II: Repeat cytoreductive surgery is recommended in progressive glioblastoma patients to improve overall survival.

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

DOI: 10.1007/s11060-021-03881-w
PMID: 35246769